(Q38014515)

27 August 2017

title

New developments in the treatment of osteoporosis (English)

1 reference

27 August 2017

0 references

Erik Fink Eriksen

1

1 reference

27 August 2017

Johan Halse

series ordinal

2

1 reference

27 August 2017

Mette Haase Moen

series ordinal

3

1 reference

27 August 2017

publication date

1 June 2013

1 reference

Acta Obstetricia et Gynecologica Scandinavica

27 August 2017

published in

1 reference

27 August 2017

volume

92

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

620-636

1 reference

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

21 January 2018

Bone mass and exercise

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Exercise as an anabolic stimulus for bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effect of Vitamin D on falls: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Prevention of hip fracture by external hip protectors: an intervention in 17 nursing homes in two municipalities in Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effect on hip fractures of increased use of hip protectors in nursing homes: cluster randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Hip protectors in aged-care facilities: a randomized trial of use by individual higher-risk residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

The effect of type of hip protector and resident characteristics on adherence to use of hip protectors in nursing and residential homes--an exploratory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Reduced bone mineral in patients with eating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Patients with eating disorders. A high-risk group for fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

21 January 2018

Diet and healthy bones.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Calcium plus vitamin D supplementation and the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Calcium/vitamin D supplementation and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Role of the vitamin D-endocrine system in the pathophysiology of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Fracture prevention with vitamin D supplementation: considering the inconsistent results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Serum 25-hydroxyvitamin D concentrations and risk for hip fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Vitamin D insufficiency and health outcomes over 5 y in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Vitamin K to prevent fractures in older women: systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Vitamin A and retinol intakes and the risk of fractures among participants of the Women's Health Initiative Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Nutrition and bone health projects funded by the UK Food Standards Agency: have they helped to inform public health policy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Avian osteoclasts as estrogen target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

The 2012 hormone therapy position statement of: The North American Menopause Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Lasofoxifene in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Molecular mechanisms of action of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Bisphosphonate adverse effects, lessons from large databases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Osteonecrosis of the jaw--a potential adverse effect of bisphosphonate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Bisphosphonates and Atypical Femoral Fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Bone mineral density thresholds for pharmacological intervention to prevent fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Progress in osteoporosis and fracture prevention: focus on postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Determinants of Bone Mineral Density in Older Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Bisphosphonates and esophageal cancer—a pathway through the confusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0412.2012.01473.X

10.1111/J.1600-0412.2012.01473.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference